|
|
|
Search for: "Truvada"
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
HSMN NewsFeed,
19 Jul 2010:
Biopharmaceuticals, HIV/AIDS
[Abbott, protease inhibitor, Kaletra, PROGRESS study]
|
Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
HSMN NewsFeed,
30 Mar 2009:
Biopharmaceuticals, Generics, FDA
[Mylan, Matrix Laboratories Limited, PEPFAR, Gilead Sciences, Truvada]
|
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
HSMN NewsFeed,
1 Aug 2008:
Biopharmaceuticals, HIV/AIDS, Distribution
[Gilead Sciences, Merck, Atripla]
|
Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
HSMN NewsFeed,
8 Jul 2008:
Biopharmaceuticals, Personnel
[Royalty Pharma]
|
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
HSMN NewsFeed,
11 Dec 2007:
Biopharmaceuticals, HIV/AIDS
[Gilead Sciences, Bristol-Myers Squibb, ATRIPLA]
|
Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
HSMN NewsFeed,
28 Nov 2007:
Biopharmaceuticals, HIV/AIDS
[Boehringer Ingelheim, NEwArT study, VIRAMUNE]
|
Significant Changes in Store for Growing HIV Market
HSMN NewsFeed,
15 Nov 2007:
Biopharmaceuticals, HIV/AIDS
[GlaxoSmithKline, Gilead, Bristol-Myers Squibb, Tibotec, Johnson & Johnson]
|
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
HSMN NewsFeed,
29 Oct 2007:
Biopharmaceuticals, HIV/AIDS
[Gilead Sciences, Truvada, emtricitabine, tenofovir, SWEET Study]
|
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
HSMN NewsFeed,
18 Oct 2007:
Biopharmaceuticals, HIV/AIDS, Regulatory
[Gilead Sciences, Bristol-Myers Squibb, Merck, ATRIPLA, efavirenz, tenofovir]
|
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
HSMN NewsFeed,
17 Oct 2007:
Biopharmaceuticals, Regulatory, HIV/AIDS
[Gilead Sciences, Bristol-Myers Squibb, ATRIPLA, antiretroviral]
|
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
HSMN NewsFeed,
18 Sep 2007:
Biopharmaceuticals, HIV/AIDS
[Tibotec Therapeutics, PREZISTA, darunavir, ritonavir, TRUVADA, ARTEMIS]
|
New Head-to-Head Study Comparing LEXIVA(R) and Atazanavir Show Similar Efficacy and Lipid Changes
HSMN NewsFeed,
25 Jul 2007:
Biopharmaceuticals, HIV/AIDS
[GlaxoSmithKline, LEXIVA, fosamprenavir, ALERT Study]
|
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
HSMN NewsFeed,
23 Jul 2007:
Biopharmaceuticals, HIV/AIDS
[Gilead Sciences, Truvada, emtricitabine, tenofovir]
|
Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
HSMN NewsFeed,
25 Jun 2007:
Biopharmaceuticals
[Gilead Sciences, Viread, tenofovir, hepatitis B]
|
Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
HSMN NewsFeed,
6 Jun 2007:
Biopharmaceuticals
[Gilead Sciences, Viread, tenofovir, hepatitis B , Hepsera, adefovir]
|
Royalty Pharma Acquires a Portion of New York University's Royalty Interest in Remicade(R) for $650 Million
HSMN NewsFeed,
4 May 2007:
Biopharmaceuticals
[Royalty Pharma, Remicade]
|
Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing Countries
HSMN NewsFeed,
16 Feb 2007:
Biopharmacetuicals, HIV/AIDS
[Merck, ATRIPLA, efavirenz, emtricitabine, tenofovir]
|
96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
HSMN NewsFeed,
15 Dec 2006:
Biopharmaceuticals, HIV/AIDS
[Gilead Sciences, Viread, Emtriva, Emtriva, Sustiva, Combivir]
|
Interim Analysis of New Study Suggests Boosted INVIRASE(R) May Achieve Similar Levels of HIV Suppression to Boosted Lopinavir with a Favorable Lipid Profile
HSMN NewsFeed,
13 Nov 2006:
Biopharmaceuticals, HIV/AIDS
[Roche , INVIRASE , protease inhibitor, antiretroviral]
|
Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA(R) From AstraZeneca and CAT
HSMN NewsFeed,
26 Oct 2006:
Biopharmaceuticals
[Royalty Pharma, Abbott, AstraZeneca, HUMIRA, adalimumab]
|
Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
HSMN NewsFeed,
9 Oct 2006:
Biopharmaceuticals, Regulatory, HIV/AIDS
[Bristol-Myers Squibb, Gilead Sciences, Merck, ATRIPLA]
|
Bristol-Myers Squibb and Gilead Sciences establish agreement to commercialize ATRIPLA(TM) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Canada
HSMN NewsFeed,
29 Sep 2006:
Biopharmaceuticals, HIV/AIDS
[Bristol-Myers Squibb, Gilead Sciences, ATRIPLA , efavirenz, emtricitabine]
|
Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
HSMN NewsFeed,
28 Sep 2006:
Biopharmaceuticals, HIV/AIDS
[Bristol-Myers Squibb, Gilead Sciences, ATRIPLA]
|
Metastatix Completes Series a Financing
HSMN NewsFeed,
7 Sep 2006:
Biopharmaceuticals, Venture Capital
[H.I.G. Ventures, Metastatix]
|
96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference
HSMN NewsFeed,
14 Aug 2006:
Biopharmaceuticals, HIV/AIDS
[Gilead Sciences, Viread, Emtriva, Sustiva, Combivir]
|
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
HSMN NewsFeed,
12 Jul 2006:
Biopharmaceuticals, FDA, HIV/AIDS
[Gilead Sciences, Bristol-Myers Squibb, ATRIPLA]
|
Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment
HSMN NewsFeed,
27 Apr 2006:
Biopharmaceuticals, HIV/AIDS, FDA
[Gilead Sciences, Bristol-Myers Squibb, Sustiva, efavirenz, Truvada]
|
U.S. FDA Grants Traditional Approval for Gilead's Once-Daily HIV Medications Truvada(R) and Viread(R)
HSMN NewsFeed,
8 Mar 2006:
Biopharmaceuticals, HIV/AIDS, FDA
[Gilead Sciences, Viread, tenofovir, Truvada, emtricitabine]
|
Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine
HSMN NewsFeed,
18 Jan 2006:
Biopharmaceuticals, HIV/AIDS
[Gilead Sciences, Viread, tenofovir disoproxil, Emtriva, Truvada]
|
Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate)
HSMN NewsFeed,
9 Jan 2006:
Biopharmaceuticals, HIV/AIDS
[Gilead Sciences, Bristol-Myers Squibb, Sustiva, Truvada]
|
|
|
 |
Additional items found:
The Network Archive contains
10 additional items
matching: Truvada
<< Members - click the icon at left to display. |
|
| |
|
|
|
|
Public
Feeds 
Full text >>